- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Canagliflozin Effective in Slowing Kidney Function Decline in Early-Stage CKD, reveals research
![Canagliflozin Effective in Slowing Kidney Function Decline in Early-Stage CKD, reveals research Canagliflozin Effective in Slowing Kidney Function Decline in Early-Stage CKD, reveals research](https://medicaldialogues.in/h-upload/2024/06/06/750x450_240303-albuminuria.webp)
A recent study published in the Kidney International found that the sodium-glucose cotransporter 2 (SGLT2) inhibitor canagliflozin may significantly slow chronic kidney disease (CKD) progression in individuals with type 2 diabetes and microalbuminuria. The CANPIONE trial investigated the efficacy of this drug in patients with early-stage CKD. It focused on the decline of kidney function measured with the help of estimated glomerular filtration rate (eGFR) slope, as well as changes in albuminuria levels.
The study included the participants with type 2 diabetes who had a urinary albumin-to-creatinine ratio (UACR) between 50 to 300 mg/g and an eGFR of at least 45 ml/min/1.73m² which signifies early-stage CKD. A total of 98 participants were randomly assigned to either receive canagliflozin or a guideline-recommended treatment excluding SGLT2 inhibitors, where 96 participants ultimately received at least one treatment dose.
The results showed a significantly greater reduction in UACR in the canagliflozin group when compared to the control group. Also, the least-squares mean change from baseline in the geometric mean UACR was 30.8% lower in the canagliflozin group which was a marked improvement over the control group. This highlighted the potential of canagliflozin in reducing albuminuria.
The eGFR slope change measured how the the kidney function of participants declined before and during treatment. A steeper slope indicates faster kidney function deterioration, while a slower slope suggests protective effects on the kidneys. The difference in eGFR slope between the canagliflozin and control groups was significant in this trial. The participants in the canagliflozin group had a 4.4 ml/min/1.73 m² per year slower decline in eGFR which demonstrated the protective effect of this drug on kidney function. This effect was even more pronounced in individuals who initially expressed a more rapid decline in eGFR which suggests the potential benefits of canagliflozin in patients at higher risk of disease progression.
The CANPIONE trial suggests that measuring the change in eGFR slope within individuals could be a novel method for evaluating the kidney-protective potential of new therapies in the early stages of CKD. Overall, the results also illuminate the potential for SGLT2 inhibitors like canagliflozin to be incorporated into early intervention strategies for CKD in patients with type 2 diabetes by potentially altering the course of the disease and improving long-term outcomes.
Reference:
Miyamoto, S., Heerspink, H. J. L., de Zeeuw, D., Sakamoto, K., Yoshida, M., Toyoda, M., Suzuki, D., Hatanaka, T., Nakamura, T., Kamei, S., Murao, S., Hida, K., Ando, S., Akai, H., Takahashi, Y., Kitada, M., Sugano, H., Nunoue, T., Nakamura, A., … Shikata, K. (2024). A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope. In Kidney International. Elsevier BV. https://doi.org/10.1016/j.kint.2024.08.019
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751